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Background: Gene expression profiling (GEP) in cells obtained from peripheral blood has shown that this is a very
useful approach for biomarker discovery and for studying molecular pathogenesis of prevalent diseases. While there
is limited literature available on gene expression markers associated with Chronic Obstructive Pulmonary Disease
(COPD), the transcriptomic picture associated with critical respiratory illness in this disease is not known at the
present moment.
Findings: By using Agilent microarray chips, we have profiled gene expression signatures in the whole blood of 28
COPD patients hospitalized with different degrees of respiratory compromise.12 of them needed of admission to
the ICU, whilst 16 were admitted to the Respiratory Medicine Service. GeneSpring GX 11.0 software was used for
performing statistical comparisons of transcript levels between ICU and non-ICU patients. Ingenuity pathway
analysis 8.5 (IPA) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to select, annotate and
visualize genes by function and pathway (gene ontology). T-test showed evidence of 1501 genes differentially
expressed between ICU and non-ICU patients. IPA and KEGG analysis of the most representative biological
functions revealed that ICU patients had increased levels of neutrophil gene transcripts, being [cathepsin G (CTSG)],
[elastase, neutrophil expressed (ELANE)], [proteinase 3 (PRTN3)], [myeloperoxidase (MPO)], [cathepsin D (CTSD)],
[defensin, alpha 3, neutrophil-specific (DEFA3)], azurocidin 1 (AZU1)], and [bactericidal/permeability-increasing
protein (BPI)] the most representative ones. Proteins codified by these genes form part of the azurophilic granules
of neutrophils and are involved in both antimicrobial defence and tissue damage. This “neutrophil signature” was
paralleled by the necessity of advanced respiratory and vital support, and the presence of bacterial infection.
Conclusion: Study of transcriptomic signatures in blood suggests an essential role of neutrophil proteases in COPD
patients with critical respiratory illness. Measurement and modulation of the expression of these genes could
present an option for clinical monitoring and treatment of severe COPD exacerbations.
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Background
Patients with Chronic Obstructive Pulmonary Disease
(COPD) suffer from periodical exacerbations, character-
ized by recurrent episodes of worsening respiratory
symptoms. Exacerbations result in further decreases in
lung function, impairing the patient’s quality of life, and
increasing the use of healthcare resources [1]. In
addition, development of Community Acquired Pneu-
monia (CAP) is also common in COPD exacerbations
[2]. Gene expression profiling (GEP) in cells obtained
from peripheral blood has proved to be a very useful
non-invasive approach for biomarker discovery and for
studying molecular pathogenesis of prevalent diseases
[3]. While there is previous work identifying gene ex-
pression markers associated with COPD using Peripheral
Blood Mononuclear Cells (PBMCs) [4], the transcrip-
tomic picture associated with critical respiratory illness
in this disease is not known at the present moment. The
objective was to describe the gene expression signatures
associated with critical COPD respiratory illness com-
pared to non-critical COPD exacerbations, as a prelim-
inary study aimed to identify the genes associated with
the severity of this disease.
Materials and methods
Patients and samples
12 patients with pre-existing diagnosis of COPD in need
of admission to the Intensive Care Unit due to acute re-
spiratory failures were compared to a group of 16 COPD
patients with non critical disease exacerbation admitted to
the Respiratory Medicine Service. 4 healthy voluntary
donors of similar ages to the patients were recruited for
gene expression data normalization. A sample of 2.5 ml of
blood was collected in the first 24 hours following admis-
sion to the ICU or to the Respiratory Medicine Service.
Acute exacerbation of COPD was defined as a patient
showing 2 symptoms (at least 1 major) for 2 consecutive
days. Major symptoms were defined as increased dys-
pnoea, sputum volume, or sputum purulence and minor
symptoms were increased cough, wheeze, sore throat, or
coryzal symptoms. Definition of CAP was based on
current American Thoracic Society and Infectious Disease
Society of America guidelines [5] . Informed consent was
obtained directly from each patient before enrolment.
Patient’s identification remained anonymous. The protocol
was approved by the Ethics Committee on Clinical Re-
search of each one of the participating centers.
Participant institutions
1. Investigación Biomédica del Clínico (ibC), Hospital
Clínico Universitario de Valladolid, Avda Ramón y
Cajal 3, 47005 Valladolid, Spain2. Infection & Immunity Medical Investigation Unit
(IMI), Microbiology and Immunology Service,
Hospital Clínico Universitario, Valladolid, Spain -
IECSCYL, 3. Critical Care Department, Hospital Son
Llatzer, Palma de Mallorca, Spain - SEMICYUC 4.
Respiratory Medicine Service, Hospital Clínico
Universitario-SACYL / SEPAR, Valladolid, Spain 5.
Critical Care Department. Parc Tauli, Hospital
Universitari de Sabadell, Spain. 6. Critical Care
Department, Hospital Clínico Universitario-SACYL/
SEMICYUC, Valladolid, Spain. 7. Critical Care
Department, Hospital Universitari Joan XXIII.
Tarragona, Spain. 8. Internal Medicine Service.
Hospital Clínico Universitario - SACYL, Valladolid,
Spain. 9. Microbiology Service, Hospital Son Llatzer,
Palma de Mallorca, Spain.
Microbial diagnosis
Sputum samples were routinely Gram stained and cul-
tured on general purpose media (blood agar, chocolate
agar, and the differentials mediums McConkey agar and
Chapman agar). Fungal infections were screened by cul-
turing sputum samples on Sabouraud agar containing
chloramphenicol [6]. Viral diagnosis was performed on
RNA from pharyngeal swabs collected in the first 24
hours following admission to the hospital by reverse
transcription-polymerase chain reaction–based methods
using reagents purchased from Roche™ (Swine Inf A/
H1N1 detection set). These samples were also assessed
by multiplex polymerase chain reaction (Luminex) with
xTAG RVP kit from Luminex-Abbott for infection with
Respiratory Syncytial Virus, Influenza B virus, Parainflu-
enza viruses 1–4, Human metapneumovirus, Entero-
viruses, Rhinovirus, Adenovirus, Bocavirus and
Coronaviruses NL63, HKU1, 229E and OC43, in accord-
ance with manufacturer’s instructions.
Microarray processing
Total RNA was extracted from blood samples using the
PAXgene Blood RNA System (PreAnalytix, Hombrechti-
kon, Switzerland). RNA was quantified by spectrometry
(NanoDrop ND1000, NanoDrop Technologies, Wilmin-
ton, Delaware USA) and quality confirmed by RNA
Experion Bioanalyzer (BioRad, California USA) assay. Up
to 1750 ng of each RNA sample was concentrated with
the RNeasy MinElute Cleanup kit (QIAGEN, Hilden,
Germany). RNA was eluted with 10 microliter of RNase-
free H2O. 300 ng of purified total RNA were used to
produce Cyanine 3-CTP-labeled cRNA using the Quick
Amp Labeling kit (Agilent p/n 5190–0442) according to
the manufacturer’s instructions. Following ‘One-Color
Microarray-Based Gene Expression Analysis’ protocol
Version 5.7 (Agilent p/n 4140–90040), 3 μg of labeled
cRNA was hybridized with Whole Human Genome
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taining 41,000+ unique human genes and transcripts.
Arrays were scanned in an Agilent Microarray Scanner
(Agilent G2565BA) according to the manufacturer’s
protocol and data extracted using Agilent Feature Extrac-
tion Software 9.5.3 following the Agilent protocol GE1-
v5_95_Feb07 and the QC Metric Set GE1_QCMT_Jan08.
Resulting microarray data sets have been uploaded to the
ArrayExpress microarray data repository [accession num-
ber: E-MEXP-3589]. Changes were verified in microarray
gene expression for representative genes of our analysis by
qPCR using Real-time Ready plates purchased to Roche,
using β-actin and β2-microglobulin as reference (house-
keeping) genes.
Data analysis
Data analysis was carried out by using GeneSpring GX
11.0 software. The original data was cleansed and nor-
malized using the robust multichip average (RMA) algo-
rithm consists of three steps: background correction,
p75 normalization and expression calculation. Subse-
quent to logarithms transformation, baseline transform-
ation of the data was performed using the median of
control samples. Before statistical analyses all microar-
rays were subjected to quality and filtering criteria.
Quality of the microarray data was assessed on Principal
Component analysis (PCA) plots. All the 32 arrays
passed these criteria and were included in the analyses.
Student T tests (GeneSpring GX11.0) were used to iden-
tify genes differentially expressed between ICU and non-
ICU groups at the level of significance p < 0.01 with
Benjamini-Hochberg multiple testing corrections. Gene-
Spring GX 11.0 was used also for performing gene hier-
archical clustering. Ingenuity pathway analysis 8.5 (IPA)
(Ingenuity Systems, Redwood City, CA) and the Kyoto
Encyclopedia of Genes and Genomes (KEGG) were used
to select, annotate and visualize genes by function and
pathway (gene ontology).
Results
Clinical description of the patients (Table 1): non-
critically ill patients were slightly older than critically ill
ones (p < 0.1). Male patients accounted for the vast ma-
jority of the cases in the non-ICU group. Sex distribu-
tion was more equal in the group of critically ill patients.
CAP at admission was more frequent in the ICU group.
No differences in the frequency of viral infection were
found between groups. On the contrary, bacterial or fun-
gal infection was more frequent in the ICU group. While
both groups showed severe hypoxemia at admission,
critically ill patients showed higher levels of CO2 in their
blood. Five critical patients needed invasive mechanical
ventilation. None of the critically ill patients showed
higher lymphocyte counts in their blood. On the contrary,critically ill patients showed higher neutrophil counts.
None of the patients died. Microbiological results revealed
the following distribution of viral and bacterial infection:
Respiratory virus infection: Non ICU group: Rhinovirus
(n= 4); Influenza A/H1N1 nv (n= 1); Metapneumovirus
(MPV) (n= 1); Coronavirus 229E (n= 1). ICU group: MPV
(n=1); Influenza A/H1N1 nv (n= 2); Respiratory Syncytial
Virus (RSV) (n= 1). Bacterial/fungal infection: Non ICU
group: P aeruginosa (n= 2); Candida glabrata (n= 1). ICU
group: A. fumigatus (n= 1); C. pneumoniae (n= 1); S.
pneumoniae (n= 3); S hominis (n = 1); P aeruginosa
(n= 1); S. epidermidis (n= 1). Co-infection (viral + bacter-
ial infection): non ICU group: [Rhinovirus + P aeruginosa]
(n= 2). ICU group: the following co-infections were found:
[Influenza A/H1N1 nv+A. fumigatus] (n= 1); [RSV+S
pneumoniae] (n= 1); [MPV+S. epidermidis] (n= 1). All
patients were treated with bronchodilators, antibiotics,
and systemic steroids (methylprednisolone i.v., 20–40 mg/
day). Treatment decisions for all patients were not stan-
dardized and were decided by the attending physician.Gene expression analysis
T-test evidenced 1501 genes differentially expressed be-
tween ICU and non ICU patients. ICU patients showed
higher expression levels of 558 genes and lower expres-
sion levels of 943 than non critically ill patients.Genes showing higher levels of RNAm transcripts in the
ICU group
IPA analysis of the most representative biological func-
tions revealed that those genes showing higher levels of
their corresponding transcripts in the ICU group partici-
pate principally in four biological functions: [immune re-
sponse] (Table 2), [severe acute respiratory syndrome],
[respiratory infection] (Table 3) and [inflammatory re-
sponse] (Table 4). Patients in the ICU group not only
showed increased neutrophil counts in blood, but also
higher levels of RNAm corresponding to a group of pro-
teins known to participate in neutrophil-mediated anti-
microbial defense and tissue injury (Figure 1).Genes showing lower levels of RNAm transcripts in the
ICU group
IPA analysis revealed that those genes showing lower
levels of their corresponding transcripts in the ICU
group participate in the immune response against patho-
gens: [Natural Killer Cell Signaling], [T Cell Receptor
Signaling], [Regulation of IL-2 Expression in Activated
and Anergic T Lymphocytes], [Transforming Growth
FActor-β Signaling], [CCR5 Signaling in Macrophages],
[CD28 Signaling in T Helper Cells] (Additional file 1:
Table S1 and Additional file 2: Table S2).
Table 1 Clinical characteristics of the patients
No ICU (n = 16) ICU (n= 12) p
Age (Mean,SD) 73.4 65.6 0.094
(9.0) (11.4)
Sex (M/F) 15/1 7/5 0.024
Community Acquired
Pneumonia (YES / NO)
3/13 8/4 0.005
Respiratory Virus (YES / NO) 7/9 4/8 n.s
Bacterial / fungal
infection (YES / NO)
3/13 8/4 0.027
PaO2 at admisión (Mean,SD) 58.7 61.9 n.s
(13.5) (22.7)
PCO2 at admisión (Mean,SD) 43.3 63.1 0.050
(14.2) (36.7)
Invasive Mechanical














Mann Whitney U test and Chi-squared test were employed to compare mean
and proportions between groups were appropriated.
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Differential expression was confirmed in samples from
all patients by qPCR. Differences between gene expres-
sion levels in the qPCR assays were assessed by perform-
ing the Mann–Whitney U test and by using SPSS 20.0
software analysis (significance was fixed at the level
p < 0.05), as shown in Additional file 3: Figure S1.
Discussion
In our study, a comprehensive GEP study was performed
on whole blood, which revealed the existence of
increased expression levels of a group of neutrophil
genes associated with antimicrobial defence and tissue
damage, as molecular signature of critical respiratory ill-
ness in COPD patients.
Genes showing increased expression in the ICU group
Neutrophil related genes
ELANE (Elastase, neutrophil expressed), CTSG (cathepsin
G), and PRTN3 (proteinase 3) are neutrophil serine pro-
teases (NSPs) produced during neutrophil development in
bone marrow and stored in the azurophilic granules of
mature neutrophils. NSPs contribute to the neutrophil
oxygen-independent system-mediated protection of the
host against invading pathogens [7]. On the other hand,
NSPs play a critical role in neutrophil-associated lung in-
flammatory and tissue-destructive diseases, includingCOPD. NSPs have a broad substrate specificity and de-
grade a variety of extra-cellular matrix proteins including
elastin, collagen (type I–IV), fibronectin, laminin and pro-
teoglycans [8]. High concentrations of NSPs are found in
purulent secretions of COPD patients[9]. Intra-tracheal
instillation of mice with human neutrophil elastase or pro-
teinase 3 leads to tissue destruction and airspace enlarge-
ment [10]. Neutrophil elastase may also impair host
defence interfering with muco-ciliary clearance of bacteria
and phagocytosis of pathogens. In turn, both elastase and
cathepsin G impair T-cell function through cleavage of
CD2, CD4 and CD8 on the surface of T-cells [8]. Patients
lacking α1-Pi, the main physiological inhibitor of neutro-
phil elastase, are at greater risk of developing emphysema
[11]. CTSD (Cathepsin D) is also present in azurophil
granules. By using a mice model, Bracke et al.. have re-
cently demonstrated that cigarette smoke induces the ex-
pression of CTSD in pulmonary macrophages [12],
supporting the role of cathepsins in the respiratory com-
promise associated to COPD . MPO (Myeloperoxidase)
constitutes the major component of neutrophil azurophi-
lic granules. MPO is important in bacterial killing, but also
drives inflammatory reactions and tissue oxidation. By
using a mice model of influenza infection, Sugamata R
et al.. found that the absence of MPO reduced inflamma-
tory damage with suppression of leakage of total proteins
in bronchoalveolar lavage fluid associated with alteration
of claudins in the lung [13]. Activated neutrophils (MPO+
cells) are found in severe COPD [14]. In this sense, inhib-
ition of MPO may be a novel and useful therapeutic treat-
ment for COPD [15]. In turn, AZU1 (azurocidin 1), BPI
(bactericidal/permeability-increasing protein) and alpha-
defensins (such as DEFA3, defensin, alpha 3, neutrophil-
specific), are as NSPs, major constituents of neutrophil
azurophilic granules. The protein encoded by AZU1 is an
antibiotic protein, with monocyte chemotactic and anti-
bacterial activity. It is also an important multifunctional
inflammatory mediator. Bactericidal/permeability-increas-
ing protein (BPI) encodes a lipopolysaccharide binding
protein with bactericidal activity on gram-negative organ-
isms. Defensins show activities against Gram-positive
and Gram-negative bacteria, fungi, yeast, and enveloped
viruses, but, as NSPs, also play important roles in promot-
ing inflammation in the lungs, potentially contributing to
lung injury [16] . Along with NSPs, defensins may also be
released upon neutrophil stimulation. Both have been
described to affect the integrity of the epithelial layer, de-
crease the frequency of ciliary beat, increase the secretion
of mucus, and induce the synthesis of epithelium-derived
mediators that may influence the amplification and reso-
lution of neutrophil-dominated inflammation [8].
A number of other gene transcripts related to
neutrophils were identified in our analysis as more repre-
sented in the ICU group: LTF (lactotransferrin), TCN1
Table 2 Gene expression levels by biological function of













LCN2 0,004 10,37 MAGEA3 0,028 3,13
LTF 0,004 9,86 LAIR1 0,013 2,99
RETN 0,014 8,85 FCAR 0,024 2,98
ELANE 0,026 8,19 PAX6 0,041 2,92
BPI 0,018 7,06 APCS 0,046 2,88
INHBA 0,007 7,12 MEFV 0,020 2,83
CHIT1 0,009 4,19 CTSD 0,037 2,82
HP 0,015 6,71 PYDC1 0,013 2,77
PRTN3 0,030 6,33 GNAO1 0,032 2,67
AZU1 0,038 6,13 ELN 0,037 2,63
CTSG 0,034 5,71 MGLL 0,023 2,61
MPO 0,024 4,97 VEGFA 0,019 2,60
CEACAM8 0,027 4,80 AKT2 0,007 2,49
PGLYRP1 0,016 4,54 GRK6 0,014 2,39
CEBPE 0,009 4,49 MAP2K3 0,045 2,37
GAST 0,020 4,09 TIMP1 0,009 2,33
PGF 0,039 4,07 ABCA7 0,007 2,32
APP 0,004 4,06 ITGAX 0,021 2,26
RNASE2 0,007 3,69 POMC 0,038 2,25
DEFA3 0,024 3,68 S100A12 0,031 3,40
BLOC1S3 0,009 3,68 TRPC2 0,034 3,37
MPP1 0,025 3,61 CAPG 0,031 2,08
CD24 0,029 3,54 KSR1 0,040 3,19
RAP1GAP 0,034 3,46 GBA 0,007 3,14
STK11 0,020 2,23 MUC1 0,030 2,06
GFI1B 0,045 2,17 GABARAPL2 0,028 2,04
BAD 0,007 2,17 C8G 0,017 2,03
CYBA 0,011 2,16 UNC13D 0,014 2,02
PRDX5 0,010 2,11 SBDS 0,033 2,01
FC: fold change of gene expression values in the ICU / non ICU group.
Table 3 Gene expression levels by biological function of
genes relatively up-regulated in the ICU group, based
upon IPA results
Severe acute respiratory syndrome & Infection of respiratory tract
IPA p-Value 5,66E-19 and 7,46E-18 respectively






















FC: fold change of gene expression values in the ICU / non ICU group.
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http://www.biomedcentral.com/1756-0500/5/401(transcobalamin I (vitamin B12 binding protein, R binder
family)) as proteins which form part of secondary granules
in neutrophils. S100A12 (S100 calcium binding protein
A12) which codifies a protein proposed to be involved in
specific calcium-dependent signal transduction pathways
and which regulatory effect on cytoskeletal components
may modulate various neutrophil activities. STXBP2 (Syn-
taxin binding protein 2) is involved in neutrophil degranu-
lation. MPP1 (Membrane protein, palmitoylated 1,
55 kDa), which participates in the regulation of neutrophilchemotaxis. FCAR (Fc fragment of IgA, receptor for): this
protein interacts with IgA-opsonized targets and triggers
several immunologic defense processes, including phago-
cytosis. ITGAX (Homo sapiens cDNA, FLJ99683) which
mediates adherence of neutrophils and monocytes to
stimulated endothelium cells, and in the phagocytosis
of complement coated particles. FCAR: this gene encodes
a receptor for the Fc region of IgA, present on the surface
of myeloid lineage cells such as neutrophils, monocytes,
macrophages, and eosinophils, and triggers several im-
munologic defence processes, including phagocytosis,
antibody-dependent cell-mediated cytotoxicity, and stimu-
lation of the release of inflammatory mediators.
This “neutrophil signature” supports the notion of the
existence at the systemic level of neutrophils ready to
fight against infection but also ready to produce media-
tors which are able to induce tissue injury. Participation
of these molecules in COPD pathogenesis had already
been described at the respiratory level, but this work is
the first suggesting an important activity of these
enzymes at the systemic level. Migration of these cells
Table 4 Gene expression levels by biological function of




































FC: fold change of gene expression values in the ICU / non ICU group.
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causative microbe, but also to damage the pulmonary
parenchyma, contributing to the explanation of the se-
verity of respiratory conditions of these patients. Finding
this “neutrophil signature” was possible since we used
whole blood instead of PBMCs for the transcriptomic
study [4]. This signature is probably related to the fact
that the vast majority of patients in the ICU group
showed bacterial infection, and neutrophils are major
actors in antibacterial defence. In fact, critically illpatients in our cohort showed significantly higher total
counts of neutrophils in blood than non-critically ill
ones. On the other hand, a limitation of our work is that
we did not isolated neutrophils for the gene expression
profiling assays. Further works targeting specific cell
types would contribute to the definition of the exact
contribution of neutrophils and other leukocytes to the
gene expression signatures linked to severe respiratory
illness in patients with COPD.
Other genes showing increased expression in the ICU group
C8G (Complement component 8, gamma polypeptide)
forms part of C8, protein which plays a central role in
assembly of the "membrane attack complex" (MAC) of
complement. The MAC is a macromolecular pore that
targets and lyses pathogens that challenge the host. De-
position of these pores on human cells contributes to
tissue damage. Interestingly, MPO products seem to be
able to activate complement [17], indicating a potential
link between MPO over-expression and induction of
MAC formation. CD24: This gene encodes a sialoglyco-
protein that is expressed on mature granulocytes and in
many B cells. Other interesting gene relatively up-
regulated in critical patients was VEGFA (Vascular endo-
thelial growth factor A). This protein is a glycosylated
mitogen that specifically acts on endothelial cells and
has various effects, including mediating increased vascu-
lar permeability, inducing angiogenesis, vasculogenesis
and endothelial cell growth, promoting cell migration,
and inhibiting apoptosis. Circulating levels of VEGF are
up-regulated in patients with acutely exacerbated COPD
and decrease after recovery from exacerbation [18]. Re-
spiratory levels of VEGF have been shown to negatively
correlate with pulmonary function in stable COPD,
which suggests its important role in COPD airway
remodelling [19]. ELN (Elastin): This gene encodes a pro-
tein that is one of the two components of elastic fibbers,
and participates in extracellular matrix organization, such
as those taking place after severe tissue injury. MUC1
(Mucin 1, cell surface associated) play an essential role in
forming protective mucous barriers on epithelial surfaces
and in the response to hypoxia. Finally, we identified
increased transcript levels in the ICU group of a group
of genes involved in antibacterial defence: PGLYRP1
(peptidoglycan recognition protein 1), CEBPE (CCAAT/
enhancer binding protein (C/EBP), epsilon), CHIT1 (chiti-
nase 1 (chitotriosidase)) and CYBA (cytochrome b-245,
alpha polypeptide).
Genes showing decreased expression in the ICU group
On the other hand, the significantly lower counts of
lymphocytes and monocytes in the blood of critically ill
patients compared to non-critically ill ones probably
explains the relatively depressed expression of immune
Figure 1 (a) Left: model depicting the physiological roles of neutrophil and complement system. Those genes with relative higher
expression in the ICU compared to the no ICU group are depicted in red (modified from KEGG) (b) One-way hierarchical clustering of neutrophil
protease genes. Signal intensity data are color-coded such that the intensity of red indicates a relatively high level of expression, while the
intensity of blue represents a relatively low level of expression.
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these cells to the site of infection (lung) or increased
apoptosis in this group of patients could contribute to
the observed lymphopenia and monocytopenia [3].
Alternatively, the presence of an increased nitro-
oxidative stress environment and the critical condition
of the most severe patients could down-modulate the
expression of genes involved in the response against
pathogens.
Conclusion
Study of transcriptomic signatures in blood suggests the
existence of an intense activity of neutrophil proteases in
COPD patients with critical respiratory illness due to a
severe exacerbation. These enzymes are involved in anti-
microbial defense but could also mediate tissue damage
in the lungs, and as a consequence this would explain
the severe respiratory failure observed in these patients.
Further studies will determine whether measurement /
modulation of the expression of these genes couldrepresent an option for clinical monitoring and treat-
ment of severe COPD exacerbations.
Availability of supporting data
The data sets supporting the results of this article are
available in the ArrayExpress repository; reference num-
ber E-MEXP-3589.
Additional files
Additional file 1: Table S1. Gene expression levels by intracellular
signalling pathway of genes relatively down-regulated in the ICU
group, based upon IPA results. FC: fold change of gene expression
values in the ICU / non ICU group.
Additional file 2: Table S2. Gene expression levels by intracellular
signalling pathway of genes relatively down-regulated in the ICU
group, based upon IPA results. FC: fold change of gene expression
values in the ICU / non ICU group.
Additional file 3: Figure S1. Gene expression levels by Quantitative
Real time PCR. Crossing points (CP) were calculated for the target gene
and for the house-keeping genes (β -actin and β2-microglobulin). The
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housekeeping genes was calculated, and the inverse of this ratio is
represented in each group of patients (ICU and no ICU). This way, the
higher the median in the box-plot, the higher is the expression of the
target gene. Differences were significant at the level p< 0.05.
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